Project Description

Adjutec Pharma

Adjutec Pharma’s vision is to develop and provide novel antibiotic resistance breakers in order to retain efficacy and facilitate reduced use of antibiotics. Its lead product is a metallo-β-lactamase resistance breaker, APC148. APC148 has demonstrated efficacy against a large panel of multidrug-resistant isolates, the synthesis route is simple and scalable, and preliminary in vitro tests indicate a favorable toxicity profile.

The management team consists of CEO Bjørn Klem, who has 30 years R&D experience at NAF-Lab, Hydro Pharma, Pronova and PhotoCur, and CSO Pål Rongved, Ph.D. in Medicinal chemistry and 22 years of leading positions in R&D/IPR at GE HealthCare and advisor to Birkeland Innovation. Adjutec Pharma was founded in 2019 in Oslo, Norway, and joined NOME in 2021.

Project Details

Company

Adjutec

MORE PROJECTS

VIEW ALL PROJECTS